Archive | Mitchell IP Law News

Covid-19 Information

Dear Friends and Clients, while our office is closed in compliance with the Covid 19 quarantine, we are still working from our home offices to protect your intellectual property.  Please do not hesitate to call us with your concerns or for teleconferences: James A. Mitchell             616 965 2431 Bruce Kanuch                     616 965 2436 […]

Continue Reading

James Mitchell Honored by Peers

Mitchell Honored by Peers As Among Best Lawyers in America We are pleased to announce that James A. Mitchell has for the twenty third year in a row been selected by his peers for inclusion in the 24th Edition of Best Lawyers in America in the practice areas of: Litigation – Intellectual Property Law, And […]

Continue Reading
Virginia-eastern

Mitchell IP LAW Alert – Celebrex Use Patent Invalid

The U.S. District Court for the Eastern District of Virginia invalidated Pfizer’s method-of-use patent on its Celebrex painkiller. The basic chemical patent on Clebrex will lapse May 30, 2014.  Pfizer hoped the method-of-use patent would allow it to maintain market exclusivity on Celebrex through Dec. 2, 2015. Pfizer currently enjoys $3 billion in annual sales from […]

Continue Reading

Mitchell IP Law Alert – Pay To Delay: FTC Finally Bags A Big One

Those engaged in the generic drug business are well familiar with the long term efforts by the Federal Trade Commission to obtain a significant anti-trust judgement in a so-called “Pay to Delay” action.  Cephalon Inc. agreed Thursday to pay $1.2 billion to settle a long-running antitrust suit.  Cephalon was accused of paying generic drug makers […]

Continue Reading